Skip to content
An Initiative of AVAC
Search
Back to Events

The New Frontier in HIV Pre-exposure Prophylaxis: Lenacapavir Update

Tuesday14October
15:30 - 16:30 GMT
Hybrid

In the ongoing search for new methods to address the HIV epidemic, the development of lenacapavir for HIV prevention is a major step forward. Findings from research studies has shown that twice-yearly injection of long-acting lenacapavir provides protection against HIV infection. This discovery offers great promise in advancing our progress towards ending AIDS as a public health threat.

In this special lecture, Moupali Das, MD, MPH, vice president, Clinical Development, HIV Prevention and Virology Pediatrics, at Gilead Sciences, will provide an update on research findings on lenacapavir for HIV prevention. Her talk will cover the status of the PURPOSE 1-5 studies, review ongoing implementation science studies, and look at the pipeline for pre-exposure prophylaxis (PrEP) at a pivotal moment for the global HIV response.

WHEN: Tuesday, October 14, 2025, 11:30 am to 12:30 pm (ET)

WHERE: Hess Commons, Mailman School of Public Health, 722 West 168th Street, New York, NY (and online)

Registration required for both in-person and online attendance.

Register to attend in person. Refreshments will be served.

Register to attend online.

Topic(s): Research

Product(s): Injectable Prep, Lenacapavir

Source(s): ICAP

Register Now

Featured Resources

Document

Lenacapavir Provider Tools and Job Aids

These editable tools, developed by Wits RHI, can be used to support providers delivering lenacapavir (LEN) for PrEP. The downloadable zip file includes: LEN Factsheet for Clients LEN Counselling Job Aid for Clinicians LEN Counselling Job Aid for Counsellors LEN Initiation Algorithm LEN Injection Procedure Chart HIV Prevention Product Comparison Table LEN Stopping and Switching…
Presentation

Prevention with PURPOSE

This presentation, delivered by Dr Linda-Gail Bekker at IAS 2025, provides an overview of PURPOSE 1 and 2 lenacapavir clinical trial results as well as special considerations for administration to different populations and drug-drug interactions.
External Link

Dynamic Choice HIV Prevention with Long-acting Injectable Cabotegravir Pre-exposure Prophylaxis in East, Central, Southern, and West Africa: A cost-effectiveness modelling analysis

In randomised controlled trials in Kenya and Uganda, a dynamic choice HIV prevention intervention that offered structured choice of biomedical prevention product and opportunity to change products over time substantially improved prevention coverage; incident HIV infections were eliminated when long-acting cabotegravir was included as an option. This article from The Lancet HIV aims to assess…
External Link

What Can Modelling Tell Us about the Scale-up of Lenacapavir for Pre-exposure Prophylaxis?

This brief provides a synthesis of evidence from mathematical modelling, as of June 2025, arising from a meeting of programme managers, civil society representatives, mathematical modellers and international HIV prevention stakeholders convened by the Gates Foundation and the Joint United Nations Programme on HIV/AIDS (UNAIDS). The meeting focused on questions currently being considered by HIV…
External Link

Empowering Women’s PrEP Choices: Qualitative Insights into Long-Acting PrEP Preferences and Decision-Making during Pregnancy and Breastfeeding in South Africa and Botswana

This article from AIDS and Behavior explores preferences for various long-acting PrEP modalities amongst pregnant and lactating people in Botswana and South Africa. It further examines participants’ HIV risk perception during pregnancy and breastfeeding, their perceived individual-level facilitators and barriers of each PrEP modality, and the support needed by participants for PrEP uptake and continuation.
External Link

Global Forecast of Long-Acting PrEP Need for Key Populations (2025–2030)

Developed by AVAC, Avenir, and Global Black Gay Men Connect, this first-of-its-kind forecast estimates: 11.16 million person-years of PrEP needed annually by 2030 among men who have sex with men, transgender women, female sex workers, and people who inject drugs Uptake scenarios for cabotegravir, lenacapavir, and oral monthly PrEP Forecasts segmented by region, population group,…
Document

Standard Operating Procedure for Injectable Lenacapavir as Pre-exposure Prophylaxis

This document, developed by the South to South Learning Network, provides an adaptable standard operating procedure (SOP) to support the development and adoption of national SOPs that align with World Health Organization recommendations and guidance on injectable lenacapavir for PrEP. Click here for a version of this resource in Word format.
External Link

The WHO and Jhpiego Provider Training Toolkit on Use of Oral and Long-Acting HIV Pre-Exposure Prophylaxis (PrEP)

This toolkit is designed to help clinicians develop knowledge and skills to provide multiple HIV PrEP methods. The toolkit includes resources for oral PrEP, long-acting cabotegravir (CAB-LA), dapivirine vaginal ring (DVR), and long-acting lenacapavir (LEN). Click here to download the full set of additional resources for this training.
External Link

Long-Acting PrEP Market Assessment for Key Populations: Global access and readiness report (2025)

This market assessment supports countries, donors, implementing partners, and advocates in making informed decisions about the introduction, scale-up, and equitable delivery of long-acting PrEP among key populations and other priority groups.
External Link

Guidelines on Lenacapavir for HIV Prevention and Testing Strategies for Long-Acting Injectable Pre-Exposure Prophylaxis

In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acquisition. In this guideline, WHO also recommends using HIV rapid diagnostic…